Polar Asset Management Partners Inc. Has $7.43 Million Stock Position in Edwards Lifesciences Corporation $EW

Key Points

• Polar Asset Management Partners Inc. significantly reduced its stake in Edwards Lifesciences Corporation by 73.7%, now holding 102,525 shares worth approximately $7.43 million after selling 287,787 shares in the first quarter.
• Edwards Lifesciences reported strong quarterly earnings, with earnings per share of $0.67, exceeding analysts' expectations, and an 11.9% year-over-year increase in revenue to $1.53 billion.
• Wall Street analysts have shown a positive outlook on Edwards Lifesciences, raising their price targets, with an average target price of $85.90 and a consensus rating of "Moderate Buy".

Polar Asset Management Partners Inc. lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 73.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 102,525 shares of the medical research company's stock after selling 287,787 shares during the quarter. Polar Asset Management Partners Inc.'s holdings in Edwards Lifesciences were worth $7,431,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in EW. Quantbot Technologies LP bought a new stake in Edwards Lifesciences during the 1st quarter worth about $26,000. Vega Investment Solutions bought a new stake in Edwards Lifesciences during the 4th quarter worth about $27,000. SouthState Corp bought a new stake in Edwards Lifesciences during the 1st quarter worth about $27,000. Global X Japan Co. Ltd. grew its holdings in Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after acquiring an additional 216 shares during the last quarter. Finally, Tradewinds Capital Management LLC grew its holdings in Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after acquiring an additional 205 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Down 1.3%

Edwards Lifesciences stock traded down $1.05 during midday trading on Thursday, hitting $77.23. 1,587,828 shares of the stock were exchanged, compared to its average volume of 4,418,590. The company has a fifty day simple moving average of $78.88 and a two-hundred day simple moving average of $75.32. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The stock has a market capitalization of $45.34 billion, a PE ratio of 11.11, a P/E/G ratio of 3.85 and a beta of 1.07. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter last year, the firm earned $0.70 EPS. Edwards Lifesciences's quarterly revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on EW shares. Deutsche Bank Aktiengesellschaft raised their target price on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research note on Friday, July 25th. Robert W. Baird raised their target price on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a research note on Friday, July 25th. Canaccord Genuity Group raised their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a research note on Friday, July 25th. Wall Street Zen raised shares of Edwards Lifesciences from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 30th. Finally, Mizuho raised their target price on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $86.45.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the sale, the insider owned 206,900 shares in the company, valued at $15,565,087. This trade represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,014 shares of company stock worth $1,698,844 in the last three months. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.